Identification and Treatment of the Liability to Develop Schizophrenia

Summary

This study seeks to determine whether adult, non-psychotic, first-degree relatives of schizophrenic patients who show specific neurocognitive deficits and negative symptoms will show improvements in these areas following a 6-month, double-blind trial of a low dose (up to 2.0 mg) of risperidone.

Timeline

Start

2003-12

Primary completion

2010-01

Completion

—

Drugs

Indications